959 related articles for article (PubMed ID: 29987671)
1. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
[TBL] [Abstract][Full Text] [Related]
2. Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer.
Lai SW; Bamodu OA; Chen JH; Wu AT; Lee WH; Chao TY; Yeh CT
Cells; 2020 Apr; 9(4):. PubMed ID: 32276472
[TBL] [Abstract][Full Text] [Related]
3. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
[TBL] [Abstract][Full Text] [Related]
4. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma.
Lehnen NC; von Mässenhausen A; Kalthoff H; Zhou H; Glowka T; Schütte U; Höller T; Riesner K; Boehm D; Merkelbach-Bruse S; Kirfel J; Perner S; Gütgemann I
Histopathology; 2013 Aug; 63(2):157-66. PubMed ID: 23808822
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity.
Zheng Q; Tang J; Aicher A; Bou Kheir T; Sabanovic B; Ananthanarayanan P; Reina C; Chen M; Gu JM; He B; Alcala S; Behrens D; Lawlo RT; Scarpa A; Hidalgo M; Sainz B; Sancho P; Heeschen C
J Exp Clin Cancer Res; 2023 Nov; 42(1):323. PubMed ID: 38012687
[TBL] [Abstract][Full Text] [Related]
7. Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma.
Lam SK; Leung LL; Li YY; Zheng CY; Ho JC
Lung Cancer; 2016 Nov; 101():111-119. PubMed ID: 27794399
[TBL] [Abstract][Full Text] [Related]
8. Long non-coding RNA CERS6-AS1 facilitates the oncogenicity of pancreatic ductal adenocarcinoma by regulating the microRNA-15a-5p/FGFR1 axis.
Yun Z; Meng F; Li S; Zhang P
Aging (Albany NY); 2021 Feb; 13(4):6041-6054. PubMed ID: 33581689
[TBL] [Abstract][Full Text] [Related]
9. NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation.
Zhuang Z; Li H; Lee H; Aguilar M; Gocho T; Ju H; Iida T; Ling J; Fu J; Wu M; Sun Y; Lu Y; Chiao PJ
Cancer Lett; 2017 Dec; 411():44-56. PubMed ID: 28951128
[TBL] [Abstract][Full Text] [Related]
10. Metallothionein-1G suppresses pancreatic cancer cell stemness by limiting activin A secretion
Li K; Zhang Z; Mei Y; Yang Q; Qiao S; Ni C; Yao Y; Li X; Li M; Wei D; Fu W; Guo X; Huang X; Yang H
Theranostics; 2021; 11(7):3196-3212. PubMed ID: 33537082
[TBL] [Abstract][Full Text] [Related]
11. Advancement of NF-κB Signaling Pathway: A Novel Target in Pancreatic Cancer.
Pramanik KC; Makena MR; Bhowmick K; Pandey MK
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30563089
[TBL] [Abstract][Full Text] [Related]
12. The inhibition of cell proliferation and induction of apoptosis in pancreatic ductal adenocarcinoma cells by verrucarin A, a macrocyclic trichothecene, is associated with the inhibition of Akt/NF-кB/mTOR prosurvival signaling.
Deeb D; Gao X; Liu Y; Zhang Y; Shaw J; Valeriote FA; Gautam SC
Int J Oncol; 2016 Sep; 49(3):1139-47. PubMed ID: 27573873
[TBL] [Abstract][Full Text] [Related]
13. SERP1 is a novel marker of poor prognosis in pancreatic ductal adenocarcinoma patients via anti-apoptosis and regulating SRPRB/NF-κB axis.
Ma Q; Wu X; Wu J; Liang Z; Liu T
Int J Oncol; 2017 Oct; 51(4):1104-1114. PubMed ID: 28902358
[TBL] [Abstract][Full Text] [Related]
14. The FGFR1 inhibitor PD173074 induces mesenchymal-epithelial transition through the transcription factor AP-1.
Nguyen PT; Tsunematsu T; Yanagisawa S; Kudo Y; Miyauchi M; Kamata N; Takata T
Br J Cancer; 2013 Oct; 109(8):2248-58. PubMed ID: 24045665
[TBL] [Abstract][Full Text] [Related]
15. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
16. GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft.
Fu J; Rodova M; Roy SK; Sharma J; Singh KP; Srivastava RK; Shankar S
Cancer Lett; 2013 Mar; 330(1):22-32. PubMed ID: 23200667
[TBL] [Abstract][Full Text] [Related]
17. Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice.
Jiang SH; Li J; Dong FY; Yang JY; Liu DJ; Yang XM; Wang YH; Yang MW; Fu XL; Zhang XX; Li Q; Pang XF; Huo YM; Li J; Zhang JF; Lee HY; Lee SJ; Qin WX; Gu JR; Sun YW; Zhang ZG
Gastroenterology; 2017 Jul; 153(1):277-291.e19. PubMed ID: 28315323
[TBL] [Abstract][Full Text] [Related]
18. Embryonic stem cell factors and pancreatic cancer.
Herreros-Villanueva M; Bujanda L; Billadeau DD; Zhang JS
World J Gastroenterol; 2014 Mar; 20(9):2247-54. PubMed ID: 24605024
[TBL] [Abstract][Full Text] [Related]
19. A novel DDIT3 activator dehydroevodiamine effectively inhibits tumor growth and tumor cell stemness in pancreatic cancer.
Zhu SL; Qi M; Chen MT; Lin JP; Huang HF; Deng LJ; Zhou XW
Phytomedicine; 2024 Jun; 128():155377. PubMed ID: 38503154
[TBL] [Abstract][Full Text] [Related]
20. Dysbindin promotes pancreatic ductal adenocarcinoma metastasis by activating NF-κB/MDM2 via miR-342-3p.
Zhu D; Zheng S; Fang C; Guo X; Han D; Tang M; Fu H; Jiang M; Xie N; Nie Y; Yao X; Chen Y
Cancer Lett; 2020 May; 477():107-121. PubMed ID: 32120026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]